Dr. Reddy’s Schedules June 2026 Analyst and Investor Meetings in Mumbai and Hyderabad
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Dr Reddy’s Laboratories ( (RDY) ) has shared an update.
On June 3, 2026, Dr. Reddy’s Laboratories announced that its management will participate in upcoming analyst and institutional investor meetings in India. The company is scheduled to attend an in-person group meeting organized by ICICI Securities in Mumbai on June 9, 2026, followed by an in-person group meeting hosted by Macquarie in Hyderabad on June 10, 2026, with the company noting that the timetable may change depending on investor or internal exigencies.
These planned conferences underscore Dr. Reddy’s ongoing engagement with the institutional investor community across domestic and international markets. Regular participation in such meetings typically helps the company communicate its strategy and business outlook to key stakeholders, potentially influencing investor sentiment and liquidity in its widely traded shares, although no specific financial or operational updates were disclosed in this notice.
The most recent analyst rating on (RDY) stock is a Buy
with a $16.90 price target.
To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock,
see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
The score is driven mainly by solid but weakening fundamentals (margin/ROE compression and higher debt despite growth) and a balanced earnings-call outlook that points to FY27 margin recovery but highlights near-term profitability and working-capital risks. Technicals are neutral-to-soft and valuation support is limited given the P/E and low yield.
To see Spark’s full report on RDY stock,
click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company headquartered in Hyderabad, Telangana, with listings in Mumbai, New York and other venues. The company develops, manufactures and markets a wide range of generic medicines and active pharmaceutical ingredients, serving regulated markets such as the U.S., Europe and key emerging economies.
Average Trading Volume: 2,524,536
Technical Sentiment Signal: Buy
Current Market Cap: $11.1B
For an in-depth examination of RDY stock, go to TipRanks’ Overview page.
